Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю.В. Акатизия: клинический анализ патологии с рекомендациями и обзором литературы. Опубликовано 10.06.2015 на портале Consilium Medicum https://con-med.ru/upload/iblock/eaa/psi_ akatisia2.pdf Доступ проверен 13.07.2020. 2. Бобров А.Е., Краснослободцева Л.А., Мутных Е.М. Психофармакология адренергической системы мозга и возможности применения Пирроксана. Психиатрия и психофармакотерапия. 2019; 20 (2): 16–30. 3. Быков Ю.В., Беккер Р.А. Пророксан в наркологии и психиатрии (часть 1). Психиатрия и психофармакотерапия. 2017;19 (2): 44–51. 4. Быков Ю.В., Беккер Р.А. Пророксан в наркологии и психиатрии (часть 2). Психиатрия и психофармакотерапия. 2017; 06: 5–61. 5. Чухловина М.Л. Особенности патогенеза, диагностики и лечения панических атак у лиц молодого возраста. Неврология, нейропсихиатрия, психосоматика. 2020; 12 (3): 37–41. 6. Agrawal R, Verma S, Halappanavar M. Measuring the Effectiveness of Benzodiazepine Prescriptions Control in Community Setting Using Prescription Drug Monitoring Program (PDMP). Community Mental Health Journal. 2020; 1: 1–6. 7. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. J Addict Med. 2018; 12(1): 4–10. 8. Aldaz P, Garjón J, Beitia G et al. Association between benzodiazepine use and development of dementia. Med Clin (Barc). 2020; S0025-7753(20)30191-3. 9. Al-Husseini A, Wazaify M, van Hout MC. Pregabalin Misuse and Abuse in Jordan: a Qualitative Study of User Experiences. Int J Ment Health Addict. 2018; 16(3): 642–654. 10. Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E. Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry. 2001; 58(2): 114–119. 11. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013; 14(2): 175–184. 12. Bushnell GA, Gerhard T, Crystal S, Olfson M. Benzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders. Pediatrics. 2020;146(1):e20193478. 13. Butler J, O'Halloran A, Leonard BE. The Galway Study of Panic Disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J Affect Disord. 1992; 26(2): 89–99. 14. Catalano G, Robeel RA, Cheney GA et al. Antidepressant Augmentation: A Review of the Literature and a Review of the Pharmacoeconomic Considerations. J Clin Psychopharmacol. 2020; 40(4): 396–400. 15. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011; 24(1): 10–17. 16. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011; 72 Suppl 1: 19–23. 17. Das M. Panic disorder: propranolol and behavioural therapy. BMJ. 2006; 332(7549): 1094. 18. Dhir A, Kulkarni SK. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neurosci Lett. 2008; 445(1): 83–88. 19. Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016; 2016: 1002. 20. Greenway SE, Pack AT, Greenway FL. Treatment of depression with cyproheptadine. Pharmacotherapy. 1995; 15(3): 357–360. 21. Gregory E, Torres IJ, Ge R et al. Predictors of cognitive impairment in treatment-resistant depression. J Affect Disord. 2020; 274: 593–601. 22. Healy D, Carney PA, Leonard BE. Monoamine-related markers of depression: changes following treatment. J Psychiatr Res. 1982–1983; 17(3): 251–260. 23. Higgins ES, George MS. Neuroscience of clinical psychiatry: the pathophysiology of behavior and mental illness. Lippincott Williams & Wilkins, 2013. 336 p. ISBN 978-1451101546. 24. Kahn RS, Asnis GM, Wetzler S, van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl). 1988; 96(3): 360–364. 25. Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res. 1988; 25(1): 101–104. 26. Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S. Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. Eur Neuropsychopharmacol. 2017; 27(5): 423–441. 27. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010; (12): CD008121. 28. Koran LM, Aboujaoude E. Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research. Curr Med Chem. 2018; 25(41): 5690–5697. 29. Kuhlman KR, Treanor M, Imbriano G, Craske MG. Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial. Psychoneuroendocrinology. 2020; 116: 104657. 30. Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011; 106(12): 2086–2109. 31. Lim J, Bang Y, Choi JH et al. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT 1A Receptor Upregulation in Mice. J Neurosci. 2018; 38(7): 1611–1621. 32. Maddock RJ, Gietzen DW, Goodman TA. Decreased lymphocyte beta-adrenoreceptor function correlates with less agoraphobia and better outcome in panic disorder. J Affect Disord. 1993; 29(1): 27–32. 33. Magliozzi JR, Gietzen D, Maddock RJ et al. Lymphocyte beta-adrenoreceptor density in patients with unipolar depression and normal controls. Biol Psychiatry. 1989; 26(1): 15–25. 34. Mash JE, Leo RJ. Phenibut: A Novel Nootropic With Abuse Potential. Prim Care Companion CNS Disord. 2020; 22(4): 19l02587. 35. Mendlewicz J, Hirsch D, Sevy S et al. Alpha-2-adrenoreceptor binding as a possible vulnerability marker for affective disorders. Neuropsychobiology. 1989; 22(2): 61–67. 36. Nankai M, Yamada S, Muneoka K, Toru M. Increased 5-HT2 receptor-mediated behavior 11 days after shock in learned helplessness rats. Eur J Pharmacol. 1995; 281(2): 123–130. 37. Pignon B, du Montcel CT, Carton L, Pelissolo A. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. Curr Psychiatry Rep. 2017; 19(12): 103. 38. Praharaj SK. Abuse Liability of Baclofen. Clin Psychopharmacol Neurosci. 2018; 16(1): 126–127. 39. Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J Clin Psychiatry. 2020; 81(3): OT19037BR3. 40. Reist C, Streja E, Tang CC et al. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectr. 2020; 1–7. 41. Salzman С. Do Benzodiazepines Cause Alzheimer's Disease? Am J Psychiatry. 2020; 177(6): 476–478. 42. Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018; 8(4): 73. 43. Schmidt P, Rao S. Effects of gabapentin, pregabalin and gastroretentive gabapentin on simulated driving, daytime sedation and cognition. Pain Manag. 2018;8(4):297-306. 44. Schneier FR, Garfinkel R, Kennedy B et al. Ondansetron in the treatment of panic disorder. Anxiety. 1996; 2(4): 199–202. 45. Smith C, Koola MM. Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder. Psychiatr Ann. 2016; 46(9): 553-555. 46. Stahl SM, Grady MM. Stahl's illustrated anxiety, stress, and PTSD. Cambridge University Press, 2010. 47. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-1107686465. 48. Stahl SM. Stahl's Illustrated Antidepressants. Cambridge University Press, 2009. 49. Steenen SA, van Wijk AJ, van der Heijden GM et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol. 2016; 30(2): 128–139. 50. Zheng KH, Khan A, Espiridion ED. Phenibut Addiction in a Patient with Substance Use Disorder. Cureus. 2019; 11(7): e5230.